Compare Natera Inc. Common Stock (NTRA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vale SA — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vale SA trades at $12.97 (market cap $57.30B). The key difference: Natera Inc. Common Stock and Vale SA are close in size by market cap, and Vale SA pays a 8.9% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vale SA for 110 Days on average.
| NTRA | VALE | |
|---|---|---|
Market Cap | $57.03B | $57.30B |
Volume | 1,131,157 | 25,010,417 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $17.82 |
52-Week Low | $179.42 | $11.10 |
Typical Hold Time | 0 Days | 110 Days |
Enterprise Value | $56.18B | $73.54B |
Dividend Yield | — | 8.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VALE trades at $13.37, down 1.11% today, with a bearish technical signal and recent earnings misses. The company reported $38.4B revenue in 2025 with net income of $2.35B, though profit margins have compressed from 42.85% in 2022 to 6.12% in 2025. Analyst consensus is mixed with 32% buy ratings and a $15.93 price target, while recent news highlights cost pressures and regulatory risks in Brazil.
The outlook remains cautious due to cyclical exposure to iron ore prices and rising operational costs. While the base metals segment shows growth potential, near-term headwinds from margin compression and earnings volatility suggest limited upside. The stock offers a dividend yield but faces significant execution and commodity price risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
